NL-OMON21542
Other
Not Applicable
Intranasal administration of oxytocin in children with Prader-Willi Syndrome. Effects on satiety and food intake, and social behaviour
Dutch Growth Research FoundationWestzeedijk 106, 3016 AH RotterdamTel: 010-2251533info@kindengroei.nl0 sites28 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Genetically confirmed diagnosis of Prader-Willi syndrome
- Sponsor
- Dutch Growth Research FoundationWestzeedijk 106, 3016 AH RotterdamTel: 010-2251533info@kindengroei.nl
- Enrollment
- 28
- Status
- Other
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Genetically confirmed diagnosis of Prader\-Willi syndrome
- •\- Age between 6 and 14 years
- •\- Currently on growth hormone treatment for at least 1 year
- •\- Increased interest in food and/or problems social behavior
Exclusion Criteria
- •\- Severe psychiatric problems
- •\- Non cooperative behaviour \- Allergic reactions or hypersensitivity for oxytocin
- •\- Serious illness
- •\- Cardiac abnormalities
- •\- Extremely low dietary intake of less than minimal required intake according to WHO
- •\- Medication to reduce weight (fat)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Withdrawn
Not Applicable
Intranasal administration of oxytocin in children with Prader-Willi Syndrome. A randomized, open-label, cross-over trial of different treatment regimens of oxytocin administration. Effects on eating behaviour and social behaviour.NL-OMON43050Stichting Kind en Groei44
Active, not recruiting
Phase 1
Intranasal administration of oxytocin in children with Prader-Willi SyndromePrader-Willi syndromeMedDRA version: 19.0Level: PTClassification code 10036476Term: Prader-Willi syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2016-003820-22-NLDutch Growth Research Foundation
Recruiting
Not Applicable
Intranasal administration of oxytocin in children with Prader-Willi Syndrome. A randomized, double-blind, placebo-controlled cross-over trial. Effects on satiety and food intake, and social behaviour.;Amendment: Six months open-label extension to the original studyPrader-Willi syndrome10083624NL-OMON41393Stichting Kind en Groei28
Active, not recruiting
Phase 1
Intranasal administration of oxytocin in children and young-adults with Prader-Willi syndromePrader-Willi syndromeMedDRA version: 17.0Level: PTClassification code 10036476Term: Prader-Willi syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2013-004134-15-NLDutch Growth Research Foundation
Terminated
Phase 4
Does intranasal oxytocin enhance emotions in dementia?Alzheimer's diseaseVascular dementiaNeurological - Alzheimer's diseaseNeurological - DementiasACTRN12617001531303niversity of Sydney4